Zentalis Pharmaceuticals, Inc.
Zentalis develops azenosertib, a WEE1 inhibitor in clinical development for ovarian cancer and multiple tumor types.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 9Latest story
Zentalis develops azenosertib, a WEE1 inhibitor in clinical development for ovarian cancer and multiple tumor types.
November 2026
October 2026
August 2026